Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes

September 1997

    Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes...and for combo use with a sulfonylurea.

    Initially, it was approved only as add-on therapy for patients poorly controlled on insulin.

    For initial therapy, Rezulin works about as well as metformin (Glucophage) or a sulfonylurea. It lowers blood sugar about 50 mg/dL...and reduces glycosylated hemoglobin (HbA1c) up to 1.5%.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote